Webbplatsen kommer inte fungerar helt korrekt om er webbläsares JavaScript funktion är inaktiverad.
}
Individual-based cancer treatment

Strike Pharma

Strike Pharma has developed a new individual-based cancer treatment, based on the genetic profile of each patient tumor, which attacks the tumor cells and leaves other normal cells in the body alone. This way you get more effective treatment while reducing the risk of side effects.

Strike Pharma

CEO:

Mårten Winge

First investment year:

2021

Business sector:

Life Science, Drug development

Investment manager: Allan Asp Visit website